HK Innoen Confirms Safety and More of Tegoprazan in US Phase 1 Clinical Trial

[Asia Economy Reporter Minji Lee] HK inno.N announced on the 7th that it has confirmed the pharmacokinetic and pharmacodynamic profiles as well as the safety and tolerability of Tegoprazan, indicated for gastroesophageal reflux disease, after conducting a Phase 1 clinical trial approved by the U.S. Food and Drug Administration (FDA).

Tegoprazan is the active ingredient of K-CAB tablets, which are already marketed domestically. The company stated, "We believe that sequential follow-up clinical trials in the U.S. will provide a positive outlook for entry into the U.S. and Canadian markets."

This content was produced with the assistance of AI translation services.